SAB Biotherapeutics Says NIH Discontinues Phase 3 ACTIV-2 Trial Of SAB-185 To Fight Covid-19
2/3 14:50
(RTTNews) - SAB Biotherapeutics (SABS) said on Wednesday that the country's primary health agency- National Institutes of Health's ACTIV-2 Program is stopping enrollment for its Phase 3 Covid-19 trial, following low hospitalization and death rates in the trial. The Phase 3 ACT...